<div><p>The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large enough to admit broadly neutralizing antibodies (bnAb). Consequently, most bnAbs must inevitably make <i>some</i> glycan contacts and avoid clashes with others. To investigate how Env glycan maturation regulates HIV sensitivity to bnAbs, we modified HIV-1 pseudovirus (PV) using various glycoengineering (GE) tools. Promoting the maturation of α-2,6 sialic acid (SA) glycan termini increased PV sensitivity to two bnAbs that target the V2 apex and one to the interface between Env surface gp120 and transmembrane gp41 subunits, typically by up to 30-fold. These effects were reversible by incubating PV with neuraminidase. The same bnAbs were...
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glyc...
The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans. The ...
The development of a protective HIV-1 vaccine remains a major challenge to the scientific community....
The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large ...
The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large ...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
Broadly neutralizing antibody (bnAb) induction is a high priority for effective HIV-1 vaccination. V...
Broadly neutralizing antibody (bnAb) induction is a high priority for effective HIV-1 vaccination. V...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
AbstractThe human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) has evolved to limit ...
In recent years the glycan shield of the HIV-1 envelope spike (Env) has emerged as a potential targe...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
SummaryA highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The hi...
The HIV-1 envelope glycoprotein trimer (Env) is covered by an extensive array of glycans that shield...
Mounting evidence suggests that glycans, rather than merely serving as a “shield”, contribute critic...
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glyc...
The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans. The ...
The development of a protective HIV-1 vaccine remains a major challenge to the scientific community....
The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large ...
The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free holes large ...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
Broadly neutralizing antibody (bnAb) induction is a high priority for effective HIV-1 vaccination. V...
Broadly neutralizing antibody (bnAb) induction is a high priority for effective HIV-1 vaccination. V...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
AbstractThe human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) has evolved to limit ...
In recent years the glycan shield of the HIV-1 envelope spike (Env) has emerged as a potential targe...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
SummaryA highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The hi...
The HIV-1 envelope glycoprotein trimer (Env) is covered by an extensive array of glycans that shield...
Mounting evidence suggests that glycans, rather than merely serving as a “shield”, contribute critic...
The human immunodeficiency virus type 1 (HIV-1) trimeric envelope glycoprotein (Env) is heavily glyc...
The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans. The ...
The development of a protective HIV-1 vaccine remains a major challenge to the scientific community....